Inhibitex, Inc.

Inhibitex announces layoffs

Published in Aging and Elder Health Week, May 28th, 2006

Inhibitex, Inc., (INHX) announced that it has reduced its workforce in order to lower its cost structure and appropriately align the company's operations with its current stage of development.

The reduction in force was largely focused in areas primarily dedicated to the planned commercialization of Veronate, the company's most advanced product candidate.

In April 2006, the company announced that a pivotal phase III clinical trial of Veronate for the prevention of hospital-associated infections in premature, low-birth-weight infants failed to meet its primary or secondary endpoints.

"We have taken immediate steps to reduce and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Aging and Elder Health Week

Source: Aging and Elder Health Week (2006-05-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry